Drug Research
Regenerons REGN-COV2 Antibody Cocktail Reduced Viral Levels and Improved Symptoms in Non-Hospitalized COVID-19 Patients
Regeneron Pharmaceuticals, Inc. announced the first data from a descriptive analysis of a seamless Phase 1/2/3 trial of its investigational antibody cocktail REGN-COV2 showing...
News
Regenerative Medicine Market Rapidly Growing Worldwide at Healthy CAGR
As per the Organ Procurement and Transplantation Network, 36,527 organ transplants were accomplished in the United States in 2020. Regenerative medicines plays a vital...
Clinical Trials
Innovent phase 3 ORIENT-32 trial of Tyvyt in combo with Byvasda to treat advanced hepatocellular carcinoma meets primary endpoints
Innovent Biologics, a biopharmaceutical company, announced the results of a phase 3, open label, randomized study in China. The ORIENT-32 trial evaluating Tyvyt (sintilimab...
News
CPhI Pharma Index: Italy and India the only pharma economies to improve score in 2020
Ahead of the CPhI Festival of Pharma (5-16 October, 2020) – global pharma’s largest ever virtual gathering – the CPhI Pharma Index shows only...
Packaging & Labelling
Aptar Pharma to Unveil its State-of-the-Art Virtual Booth at CPhI Festival of Pharma
Aptar Pharma, a global leader in drug delivery systems, services and active packaging solutions, is pleased to announce its Platinum Sponsorship of the CPhI...
Press Releases
PCI Pharma Services Introduces First-of-its-Kind Digital Platform to Provide Clients with Real-Time Supply Chain Data and Analytics
PCI Pharma Services (PCI), announced the launch of pci | bridge, an innovative digital platform that will give customers immediate visibility into their clinical...
Clinical Trials
Anti-influenza drug Avigan Tablet Meets Primary Endpoint in Phase III Clinical Trial in Japan for COVID-19 patients
FUJIFILM Toyama Chemical Co., Ltd. has announced that primary endpoint has been met in phase III clinical trial of “Avigan Tablet” conducted in Japan...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read